Tagraxofusp, a CD123‐directed antibody conjugate, was recently approved for the treatment of BPDCN, but serious adverse events were common in adults and the clinical efficacy was disappointing.22 This evidence concerns the gene IL3RA and CD4+/CD56+ hematodermic neoplasm.